Neurostimulation for the Relief of Acute Bronchoconstriction

Asthma Clinical Trial

Official title:

Neurostimulation for the Relief of Acute Bronchoconstriction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00762931
• Other study ID #: BC-01
• Status: Completed
• Phase: N/A
• Start date: September 2008
• Est. completion date: October 2010

Study information

• Verified date: April 2018
• Source: ElectroCore LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to validate design for the Resolve™ Stimulator and Proximity Electrode and the associated procedure to quickly and safely place an electrode into the neck, in the vicinity of the vagus nerve by a physician in either the Emergency Department or other appropriate hospital inpatient setting (e.g., ICU). The secondary goal is to confirm that the electrical signal being delivered via this electrode rapidly counters bronchoconstriction and improves airway flow.

Description:

The present study is to evaluate the safety of a new neurostimulator device, the Resolve Stimulator and Proximity Lead™, which comprises an external electrical signal generator coupled to temporary electrode that is percutaneously inserted in the neck.

Sponsor believes, based on animal testing data provided as well as consultations with physicians who regularly treat patients suffering from attacks of acute bronchoconstriction in ER and inpatient hospital settings, that this device could be used in the skilled care hospital setting to help rapidly relax the smooth muscle in the airway, relieving a clinically significant portion of the bronchoconstriction suffered by patients experiencing moderate to severe asthma attacks, allowing more effective delivery of inhaled medications to restore the patient to his or her baseline respiration status.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: October 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male / Female, Age 18-65

• Subject declares a medical history of asthma or sufficient prior clinical experience/records exists to confirm the subject has received a diagnosis of bronchoconstriction

• Completed >1 hrs of conventional breathing and related medication treatments without improvement in FEV1 to > 70% predicted

• Able to give Informed Consent

Exclusion Criteria:

• Scaring / abscess other problems with neck at electrode placement site

• Known or suspected carotid artery disease (i.e. bruits or history of stenosis)

• Suspected or confirmed coagulopathy

• Suspected or confirmed sepsis

• Irregular heart rate, rhythm

• Receiving pressors to maintain blood pressure

• Presently implanted electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant

• Allergy to local anesthetics used for placement of the lead

• History of lung cancer, emphysema, chronic obstructive pulmonary disease, or other comorbidity that might otherwise compromise the expected air flow volumes in the lungs

• At risk of imminent respiratory collapse

• Lung Function: FEV1 < 40% predicted

• Signs and Symptoms: Extreme symptoms at rest, accessory muscle use, chest retraction

• Alert State: Drowsy, confused

• Treatment with anti-cholinergic medications within 4 hours of enrollment

Related Conditions & MeSH terms

• Asthma

Intervention

Device:
• Resolve Stimulator and Proximity Lead
An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation

Locations

Country	Name	City	State
United States	Rush University Medical Center	Chicago	Illinois
United States	Henry Ford Health System	Detroit	Michigan
United States	Dorrington Medical Associates	Houston	Texas
United States	Hennepin County Medical Center	Minneapolis	Minnesota
United States	William Beaumont Hospital	Royal Oak	Michigan
United States	Washington University School of Medicine, Barnes-Jewish Hospital,	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
ElectroCore LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety- Number of Participants With Adverse Events	Safety- Number of participants that reported Adverse Events	2 weeks
Secondary	Improvement of Common Measures of Breathing Performance, Forced Expiry Volume in 1second (FEV1).	An assessment of Forced Expiry Volume in 1second (FEV1) measurements were taken throughout the course of treatment (15,30 and 60 minutes).; Peak FEV1 measurements were recorded for each subject, and the number of minutes the subject had received treatment at the time of peak FEV1.; The threshold for improvement was set at 12% over baseline at any of the time points (15,30 and 60 minutes). Outcome measure data indicates the number of subjects above 12%.	60 minutes